ECSP045469A - El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas - Google Patents

El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas

Info

Publication number
ECSP045469A
ECSP045469A EC2004005469A ECSP045469A ECSP045469A EC SP045469 A ECSP045469 A EC SP045469A EC 2004005469 A EC2004005469 A EC 2004005469A EC SP045469 A ECSP045469 A EC SP045469A EC SP045469 A ECSP045469 A EC SP045469A
Authority
EC
Ecuador
Prior art keywords
cyanopirrolidins
replaced
preparations containing
associated diseases
combination preparations
Prior art date
Application number
EC2004005469A
Other languages
English (en)
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045469A publication Critical patent/ECSP045469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2004005469A 2002-06-03 2004-12-01 El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas ECSP045469A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03

Publications (1)

Publication Number Publication Date
ECSP045469A true ECSP045469A (es) 2005-01-28

Family

ID=29712145

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005469A ECSP045469A (es) 2002-06-03 2004-12-01 El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas

Country Status (25)

Country Link
US (2) US20050176806A1 (enExample)
EP (1) EP1513519B1 (enExample)
JP (2) JP2005532338A (enExample)
KR (1) KR20050012771A (enExample)
CN (2) CN100402026C (enExample)
AT (1) ATE422884T1 (enExample)
AU (2) AU2003245903B2 (enExample)
BR (1) BR0311535A (enExample)
CA (1) CA2487297C (enExample)
CY (1) CY1112800T1 (enExample)
DE (1) DE60326232D1 (enExample)
DK (1) DK1513519T3 (enExample)
EC (1) ECSP045469A (enExample)
ES (1) ES2321600T3 (enExample)
IL (1) IL165181A (enExample)
MX (1) MXPA04012149A (enExample)
NO (1) NO333585B1 (enExample)
NZ (1) NZ536832A (enExample)
PL (1) PL210408B1 (enExample)
PT (1) PT1513519E (enExample)
RU (1) RU2362555C2 (enExample)
SG (1) SG154333A1 (enExample)
SI (1) SI1513519T1 (enExample)
WO (1) WO2003101448A1 (enExample)
ZA (1) ZA200409136B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402026C (zh) * 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP5122144B2 (ja) * 2004-01-20 2013-01-16 ノバルティス アーゲー 直接圧縮製剤および方法
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008097535A2 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
EA202192328A1 (ru) * 2019-03-22 2022-02-21 Раш Юниверсити Медикал Сентер Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
TW222626B (enExample) * 1991-07-22 1994-04-21 Pfizer
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
JP2005507261A (ja) * 2001-10-31 2005-03-17 ノバルティス アクチエンゲゼルシャフト Tcf1遺伝子における多型に基づく糖尿病および関連状態の治療方法
PE20040291A1 (es) * 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CN100402026C (zh) * 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds
AU2006292377B2 (en) * 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events

Also Published As

Publication number Publication date
ES2321600T3 (es) 2009-06-09
PL210408B1 (pl) 2012-01-31
BR0311535A (pt) 2005-02-22
AU2003245903A1 (en) 2003-12-19
IL165181A (en) 2010-06-16
PT1513519E (pt) 2009-05-06
IL165181A0 (en) 2005-12-18
AU2003245903B2 (en) 2006-11-30
EP1513519A1 (en) 2005-03-16
ZA200409136B (en) 2005-07-27
HK1074794A1 (en) 2005-11-25
SG154333A1 (en) 2009-08-28
CA2487297A1 (en) 2003-12-11
US20120014907A1 (en) 2012-01-19
AU2006246483B9 (en) 2010-08-12
JP2010155866A (ja) 2010-07-15
JP2005532338A (ja) 2005-10-27
ATE422884T1 (de) 2009-03-15
PL374016A1 (en) 2005-09-19
CN1658867A (zh) 2005-08-24
MXPA04012149A (es) 2005-04-19
RU2362555C2 (ru) 2009-07-27
CY1112800T1 (el) 2016-02-10
CN101273987A (zh) 2008-10-01
RU2004139029A (ru) 2005-08-27
SI1513519T1 (sl) 2009-06-30
CA2487297C (en) 2011-08-09
CN100402026C (zh) 2008-07-16
NO333585B1 (no) 2013-07-15
AU2006246483A1 (en) 2006-12-21
DK1513519T3 (da) 2009-06-02
EP1513519B1 (en) 2009-02-18
AU2006246483B2 (en) 2010-06-24
NZ536832A (en) 2006-11-30
WO2003101448A1 (en) 2003-12-11
US20050176806A1 (en) 2005-08-11
DE60326232D1 (de) 2009-04-02
KR20050012771A (ko) 2005-02-02
NO20045452L (no) 2005-03-01

Similar Documents

Publication Publication Date Title
BR0311535A (pt) Uso de cianopirrolidinas substituìdas e preparações de combinações contendo as mesmas para o tratamento da hiperlipidemia e doenças associadas
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE381535T1 (de) Phenethanolaminderivate
EE200300324A (et) Asendatud alküülamiini derivaadid ja nende kasutamismeetodid
SE0104340D0 (sv) New compounds
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ES2284970T3 (es) Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer.
ATE228134T1 (de) Kondensierte pyrimidinderivate und diese enthaltende pharmazeutische zubereitungen
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
EP1325918A4 (en) INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE
DE60312154D1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
DE60008430D1 (de) Verbindungen mit antithrombotischer wirkung
BR0206322A (pt) Derivados de pirrolopiridinona substituìdos úteis como inibidores de fosfodiesterase
ES2157258T3 (es) Inhibidores de la reincorporacion de dopamina destinados para el tratamiento del sindrome de parkinson.
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma